Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $37.98 USD
Change Today +0.65 / 1.74%
Volume 1.2M
JUNO On Other Exchanges
Symbol
Exchange
NASDAQ GS
As of 5:20 PM 08/28/15 All times are local (Market data is delayed by at least 15 minutes).

juno therapeutics inc (JUNO) Snapshot

Open
$37.00
Previous Close
$37.33
Day High
$39.00
Day Low
$37.00
52 Week High
06/5/15 - $69.28
52 Week Low
08/24/15 - $33.00
Market Cap
3.8B
Average Volume 10 Days
1.8M
EPS TTM
--
Shares Outstanding
100.6M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for JUNO THERAPEUTICS INC (JUNO)

juno therapeutics inc (JUNO) Related Businessweek News

No Related Businessweek News Found

juno therapeutics inc (JUNO) Details

Juno Therapeutics, Inc., a biopharmaceutical company, engages in developing cell-based cancer immunotherapies. The company develops cell-based cancer immunotherapies based on its chimeric antigen receptor and T cell receptor technologies to genetically engineer T cells to recognize and kill cancer cells. Its clinical stage CD19 product candidates include JCAR015 that is in Phase I clinical trials for adult patients with relapsed/refractory B cell acute lymphoblastic leukemia (r/r ALL); JCAR017, which is in Phase I/II trials for pediatric patients with r/r ALL; and JCAR014 that is in Phase I/II trials to treat various B cell malignancies in patients relapsed or refractory to standard therapies. The company’s additional product candidates comprise CD22, a cell surface protein expressed on B lymphocytes; CD171, a cell-surface adhesion molecule to treat neuroblastoma; MUC-16, a protein for treating ovarian cancers; IL-12, a cytokine to overcome the inhibitory effects; ROR-1, a protein for the treatment of non-small cell lung, triple negative breast, pancreatic, and prostate cancers; and WT-1, an intracellular protein that is in Phase I/II clinical trials to treat adult myeloid leukemia and non-small cell lung, breast, pancreatic, ovarian, and colorectal cancers. Juno Therapeutics, Inc. has collaboration agreements with Fred Hutchinson Cancer Research Center, Memorial Sloan Kettering Cancer Center, and Seattle Children’s Research Institute. The company was formerly known as FC Therapeutics, Inc. and changed its name to Juno Therapeutics, Inc. in October 2013. Juno Therapeutics, Inc. was founded in 2013 and is headquartered in Seattle, Washington.

206 Employees
Last Reported Date: 08/14/15
Founded in 2013

juno therapeutics inc (JUNO) Top Compensated Officers

Co-Founder, Chief Executive Officer, Presiden...
Total Annual Compensation: $671.0K
Chief Financial Officer and Head of Corporate...
Total Annual Compensation: $383.5K
Executive Vice President of Research & Develo...
Total Annual Compensation: $566.7K
Compensation as of Fiscal Year 2014.

juno therapeutics inc (JUNO) Key Developments

Juno Therapeutics Inc. Announces Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2015; Provides Earnings Guidance for the Year 2015

Juno Therapeutics Inc. announced unaudited consolidated earnings results for the second quarter and six months ended June 30, 2015. For the quarter, the company reported net loss attributable to common stockholders of $66 million or $0.79 per basic and diluted share on revenue of $12.5 million compared to net loss attributable to common stockholders of $38.1 million or $5.80 per basic and diluted share reported in the same period last year. Loss from operations was $68 million against $12.7 million reported last year. Loss before income taxes was $67.6 million against $22.8 million reported last year. Non-GAAP net loss attributable to common stockholders was $29.5 million or $0.35 per basic and diluted share against $12.5 million or $1.90 per basic and diluted share reported last year. For the six months, the company reported net loss attributable to common stockholders of $130.9 million or $1.58 per basic and diluted share on revenue of $12.5 million compared to net loss attributable to common stockholders of $47.1 million or $7.06 per basic and diluted share reported in the same period last year. Loss from operations was $133.1 million against $21.0 million reported last year. Loss before income taxes was $132.5 million against $31.7 million reported last year. Non-GAAP net loss attributable to common stockholders was $53.7 million or $0.65 per basic and diluted share against $20.6 million or $3.09 per basic and diluted share reported last year. Juno expects 2015 cash burn, excluding cash inflows or outflows from business development activities and the now-settled litigation, to be at the higher end of its guidance of between $125 million and $150 million.

Juno Therapeutics Inc. to Report Q2, 2015 Results on Aug 12, 2015

Juno Therapeutics Inc. announced that they will report Q2, 2015 results After-Market on Aug 12, 2015

Juno Therapeutics Inc., Q2 2015 Earnings Call, Aug 12, 2015

Juno Therapeutics Inc., Q2 2015 Earnings Call, Aug 12, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
JUNO:US $37.98 USD +0.65

JUNO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for JUNO.
View Industry Companies
 

Industry Analysis

JUNO

Industry Average

Valuation JUNO Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 250.8x
Price/Book 10.1x
Price/Cash Flow NM Not Meaningful
TEV/Sales 276.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact JUNO THERAPEUTICS INC, please visit www.junotherapeutics.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.